Supriya Lifescience (SUPRIYA) Aktienübersicht
Supriya Lifescience Limited beschäftigt sich mit der Forschung und Entwicklung, der Herstellung und dem weltweiten Verkauf von Arzneimitteln und pharmazeutischen Chemikalien. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 2/6 |
SUPRIYA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Supriya Lifescience Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹797.15 |
| 52-Wochen-Hoch | ₹1,085.00 |
| 52-Wochen-Tief | ₹545.50 |
| Beta | 0.67 |
| 1 Monat Veränderung | -5.16% |
| 3 Monate Veränderung | 2.07% |
| 1 Jahr Veränderung | 20.37% |
| 3 Jahre Veränderung | 197.78% |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | 103.95% |
Aktuelle Nachrichten und Updates
Recent updates
Narrative-Update • Jun 16
SUPRIYA: USFDA VAI Outcome And Exports Will Shape Balanced Stock Outlook
Analysts have maintained their price target for Supriya Lifescience at ₹940, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Supriya Lifescience Supriya Lifescience has scheduled a board meeting on May 27, 2026, to consider and approve audited financial results for the quarter and financial year ended March 31, 2026, and to consider a dividend on equity shares for the same period.Narrative-Update • Jun 02
SUPRIYA: USFDA VAI Outcome Will Signal Downside Risk To Export Reliance
Analysts have maintained their price target for Supriya Lifescience at ₹940. The steady figure reflects updated assumptions of lower revenue growth, slightly higher profit margins, and a marginally reduced future P/E outlook.Analyseartikel • May 23
With EPS Growth And More, Supriya Lifescience (NSE:SUPRIYA) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative-Update • May 10
SUPRIYA: USFDA VAI Outcome Will Drive April 2026 Board Decisions
Analysts have kept Supriya Lifescience's fair value estimate steady at ₹940, indicating that recent tweaks to assumptions such as the discount rate and future P/E are seen as refinements rather than drivers of a changed price target. What's in the News USFDA issued an Establishment Inspection Report with a Voluntary Action Indicated classification for Supriya Lifescience's API facility at Lote Parshuram, Maharashtra, closing the February 2 to February 6, 2026 inspection cycle and confirming ongoing cGMP compliance (Regulatory filing).Narrative-Update • Apr 26
SUPRIYA: Bullish View Will Center On April 2026 Board And Director Decisions
Analysts have kept their price target for Supriya Lifescience steady at ₹940, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A special or extraordinary shareholders meeting is scheduled for April 10, 2026 via postal ballot in India to consider appointing Mr. Manish Panchal as a non executive independent director for a five year term from February 9, 2026 to February 8, 2031 (Key Developments).Narrative-Update • Apr 08
SUPRIYA: Bullish View Will Focus On April 2026 Shareholder Decisions
Analysts have kept Supriya Lifescience's fair value estimate steady at ₹940. This reflects unchanged views on its discount rate, revenue growth outlook, profit margin expectations and future P/E assumptions.Narrative-Update • Mar 25
SUPRIYA: Bullish View Will Await April 2026 Shareholder Meeting Outcome
Analysts are maintaining their fair value estimate for Supriya Lifescience at ₹940 per share. This reflects unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, which together support a steady view on the company’s valuation outlook.Narrative-Update • Mar 11
SUPRIYA: Bullish View Will Await February 2026 Results As Key Catalyst
Analysts have kept their price target for Supriya Lifescience steady at ₹940, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The board has scheduled a meeting for Feb 09, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narrative-Update • Feb 24
SUPRIYA: Steady Thesis Will Rely On Upcoming February 2026 Results Catalyst
Analysts have kept their fair value estimate for Supriya Lifescience steady at ₹940. They explain the unchanged price target by relatively similar assumptions on revenue growth, profit margins and future P/E compared with their prior model.Narrative-Update • Feb 10
SUPRIYA: Future Returns Will Reflect Steady Thesis And Upcoming Results Catalyst
Analysts have kept their fair value estimate for Supriya Lifescience steady at ₹940.0, with the latest tweak in assumptions mainly reflecting a slightly adjusted discount rate and future P/E expectations rather than a change in the underlying thesis. What's in the News A board meeting is scheduled for February 9, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analyseartikel • Jan 29
Supriya Lifescience Limited's (NSE:SUPRIYA) Business Is Yet to Catch Up With Its Share Price
With a price-to-earnings (or "P/E") ratio of 29.2x Supriya Lifescience Limited ( NSE:SUPRIYA ) may be sending bearish...Narrative-Update • Jan 26
SUPRIYA: Future Returns Will Reflect Higher P E Expectations And Earnings Visibility
Analysts have lifted their fair value estimate for Supriya Lifescience from ₹850 to ₹940, citing updated assumptions around future P/E levels while keeping growth, margins and the discount rate broadly unchanged. What's in the News Board meeting scheduled for Nov 12, 2025, at 15:00 Indian Standard Time to consider and approve unaudited financial results for the quarter and half year ended Sep 30, 2025, along with the statutory auditors' limited review report (company filing).Narrative-Update • Jan 10
SUPRIYA: Future Returns Will Reflect Stable Board Oversight And Dividend Confidence
Analysts have maintained their fair value estimate for Supriya Lifescience at ₹850.0. This reflects unchanged views on discount rate, revenue growth, profit margin and future P/E assumptions that continue to support this target. What's in the News Board meeting scheduled for November 12, 2025, at 15:00 Indian Standard Time, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).Narrative-Update • Dec 17
SUPRIYA: Future Returns Will Reflect WHO GMP Certification And Dividend Confidence
Analysts have maintained their price target for Supriya Lifescience at ₹850.00 per share, citing stable assumptions on the discount rate, revenue growth, profit margins, and future valuation multiples as justification for keeping their outlook unchanged. What's in the News World Health Organisation grants WHO GMP certification for inhalation dosages at Supriya Lifescience's Ambernath facility, enabling production, sale, and wider global distribution from the site (Regulatory filing).Narrative-Update • Dec 03
SUPRIYA: Future Returns Will Reflect WHO GMP Certification-Driven Expansion
Analysts have modestly reiterated their conviction in Supriya Lifescience with an unchanged fair value estimate of ₹850.00 per share, reflecting stable assumptions on growth, profitability, and valuation multiples. What's in the News The World Health Organization has granted WHO GMP certification for Supriya Lifescience’s Ambernath facility for inhalation dosages, enabling production, sale, and wider global distribution from the site (Regulatory filing).Narrative-Update • Nov 19
SUPRIYA: Future Performance To Reflect Improved Margins And WHO-GMP Certification
Analysts have raised their price target for Supriya Lifescience from ₹800 to ₹850, citing stronger revenue growth projections and improved profit margins. What's in the News The board meeting is scheduled for November 12, 2025 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025.Narrative-Update • Aug 23
Expansion Into Regulated Markets And CMO/CDMO Opportunities To Strengthen Future Prospects
Despite a substantial increase in consensus revenue growth forecasts and a notable reduction in future P/E, analysts have revised Supriya Lifescience’s fair value down from ₹843 to ₹800. What's in the News Board meeting scheduled to approve unaudited financial results for the quarter ended June 30, 2025.Analyseartikel • Jul 03
Supriya Lifescience Limited's (NSE:SUPRIYA) Shareholders Might Be Looking For Exit
It's not a stretch to say that Supriya Lifescience Limited's ( NSE:SUPRIYA ) price-to-earnings (or "P/E") ratio of...Analyseartikel • Apr 04
Here's Why We Think Supriya Lifescience (NSE:SUPRIYA) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Mar 04
Subdued Growth No Barrier To Supriya Lifescience Limited's (NSE:SUPRIYA) Price
It's not a stretch to say that Supriya Lifescience Limited's ( NSE:SUPRIYA ) price-to-earnings (or "P/E") ratio of...
Neues Narrative • Feb 11
Expansion Into High-Margin Therapeutic Segments Like Anti-Stimulants Will Strengthen Future Prospects
Expanding into high-margin therapeutic segments and increasing exports highlight Supriya Lifescience's potential for robust future revenue growth.Analyseartikel • Nov 07
Supriya Lifescience Limited (NSE:SUPRIYA) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Supriya Lifescience Limited ( NSE:SUPRIYA ) shares have continued their recent momentum with a 26% gain in the last...Analyseartikel • Sep 08
Supriya Lifescience (NSE:SUPRIYA) Has Announced That It Will Be Increasing Its Dividend To ₹0.80
The board of Supriya Lifescience Limited ( NSE:SUPRIYA ) has announced that it will be paying its dividend of ₹0.80 on...Analyseartikel • Jun 05
We Think You Should Be Aware Of Some Concerning Factors In Supriya Lifescience's (NSE:SUPRIYA) Earnings
Supriya Lifescience Limited's ( NSE:SUPRIYA ) healthy profit numbers didn't contain any surprises for investors...Analyseartikel • May 10
Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
With a price-to-earnings (or "P/E") ratio of 24.6x Supriya Lifescience Limited ( NSE:SUPRIYA ) may be sending bullish...Analyseartikel • Feb 09
Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider...Analyseartikel • May 28
Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
The recent earnings posted by Supriya Lifescience Limited ( NSE:SUPRIYA ) were solid, but the stock didn't move as much...Analyseartikel • May 07
Market Cool On Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings Pushing Shares 27% Lower
The Supriya Lifescience Limited ( NSE:SUPRIYA ) share price has fared very poorly over the last month, falling by a...Aktionärsrenditen
| SUPRIYA | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 1.7% | -0.3% | -0.2% |
| 1Y | 20.4% | 14.6% | 2.4% |
Rendite im Vergleich zur Industrie: SUPRIYA übertraf die Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 14.6 erzielte.
Rendite vs. Markt: SUPRIYA übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 2.4 erzielte.
Preisvolatilität
| SUPRIYA volatility | |
|---|---|
| SUPRIYA Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stabiler Aktienkurs: Der Aktienkurs von SUPRIYA war in den letzten 3 Monaten im Vergleich zum Indian -Markt volatil.
Volatilität im Zeitverlauf: SUPRIYADie wöchentliche Volatilität (10%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der Indian Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1987 | 515 | Saloni Wagh | www.supriyalifescience.com |
Supriya Lifescience Limited beschäftigt sich mit der Forschung und Entwicklung, der Herstellung und dem weltweiten Verkauf von Arzneimitteln und pharmazeutischen Chemikalien. Das Unternehmen bietet pharmazeutische Wirkstoffe in den Bereichen Antihistaminika, Antiallergika, Antiasthmatika, abschwellende Mittel, Analgetika/Antipyretika/Anästhetika, Antihypertonika, Malariamittel, Vitamine, Malariamittel und Mittel gegen Gicht. Das Unternehmen bietet auch Produkte für die Onkologie, die Tiermedizin und die allgemeine Kategorie an.
Supriya Lifescience Limited's Grundlagenzusammenfassung
| SUPRIYA grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹64.82b |
| Gewinn(TTM) | ₹1.98b |
| Umsatz(TTM) | ₹8.73b |
32.3x
Kurs-Gewinn-Verhältnis 7.4x
Kurs-Umsatz-VerhältnisIst SUPRIYA zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| SUPRIYA Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹8.73b |
| Kosten der Einnahmen | ₹2.79b |
| Bruttogewinn | ₹5.94b |
| Sonstige Ausgaben | ₹3.96b |
| Gewinn | ₹1.98b |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 24.65 |
| Bruttomarge | 68.06% |
| Nettogewinnspanne | 22.74% |
| Schulden/Eigenkapital-Verhältnis | 0.5% |
Wie hat sich SUPRIYA auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.1%
Aktuelle Dividendenrendite4%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/24 11:35 |
| Aktienkurs zum Tagesende | 2026/08/24 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Supriya Lifescience Limited wird von 2 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Maitri Sheth | Choice Equity Broking Private Limited |
| null null | K.R. Choksey Shares & Securities Private Ltd. |